**Embargoed until: June 21, 2016, 11.00 a.m.**

**Evonik increases the value of its innovation pipeline by half a billion euros**

• Evonik innovation campaign bears fruit—innovative power considerably enhanced

• In the medium term, Evonik aims for products and applications developed in the past five years to account for over 16 percent of sales

• Growth fields should generate over €1 billion in additional sales by 2025

Evonik Industries is strengthening its innovative power. Last year, the specialty chemicals company increased the value of its innovation pipeline by half a billion euros. This now places the value of the pipeline in the lower single-digit billion euro range—a figure that is expected to continue growing over the next few years. At today’s R&D press briefing in Essen, Germany, Chairman of the Executive Board of Evonik Industries Klaus Engel said: “Our innovation campaign is bearing fruit. The constant flow of new products, applications, and business models is a major driver of

profitable growth at Evonik. Innovations are to make an even larger contribution to sales and profit going forward.” In the medium

term, the Group aims for products and applications developed in the past five years to account for over 16 percent of sales. Currently, these constitute around 10 percent of sales.

“It’s an ambitious goal,” said Evonik Chief Innovation Officer Ulrich Küsthardt, “and we have taken additional steps in order to meet it.” Evonik has brought its innovation portfolio into focus, redefined its growth fields, and taken the development of its innovation culture still further. Küsthardt said, “We have a total of six growth fields, which we expect to contribute over €1 billion in additional sales by the year 2025.” These fields are in highly attractive markets where Evonik can offer new products and solutions in line with its core competencies. Examples here include sustainable nutrition, healthcare solutions, and cosmetic solutions.

Reorganizing these growth fields goes hand in hand with focusing on the innovation portfolio. The streamlined innovation portfolio now includes a more significant portion of larger innovation

June 21, 2016

**Economic press contact**

**Edda Schulze**

Corporate Press

Phone +49 201 177-2225

Fax +49 201 177-3030

[edda.schulze@evonik.com](mailto:edda.schulze@evonik.com)

**Evonik Industries AG** Rellinghauser Straße 1-11

45128 Essen

Germany

Phone +49 201 177-01

Telefax +49 201 177-3475

[www.evonik.com](http://www.evonik.com/)

**Supervisory Board**

Dr. Werner Müller, Chairman

**Executive Board**

Dr. Klaus Engel, Chairman

Christian Kullmann, Deputy Chairman

Dr. Ralph Sven Kaufmann

Thomas Wessel

Ute Wolf

Registered office Essen

Registered court

Essen local court

Commercial registry B 19474

VAT ID no. DE 811160003

projects, as well as those to be carried out over the medium and long term. This will allow the company to make more efficient use of resources. Idea competitions and fostering entrepreneurship represent additional ways of improving the culture of innovation.

The planned acquisition of the specialty additives business (the Performance Materials Division) of US-based Air Products is likewise expected to strengthen Evonik’s innovative power in the field of specialty additives. Air Products’ specialty additives business employs excellent R&D personnel and maintains a powerful R&D pipeline.

“We want to become one of the most innovative companies in the world,” said Küsthardt, underscoring the ambitions of the specialty chemicals company. According to a Forsa survey, nearly 50 percent of those surveyed trust Evonik to meet this goal over the medium term. Over 75 percent of those surveyed see Evonik as an

innovative company. Early this year, Evonik contracted Forsa, an independent opinion research institute, to conduct the survey among select target groups, such as customers, investors, politicians, scientists, and employees.

R&D at Evonik 2015

R&D expenditures €434 million

R&D expenditures, 2010 – 2015 Average increase: 6% per year

Rate of R&D investment 3.2 % Portion of sales tied to products and applications developed

in the past five years Roughly 10%

Development of innovation pipeline value, 2014 – 2015 Increase of €500 million

Sales of patented products 57%

Number of new patent applications submitted in 2015 Roughly 260

Portfolio of patents and patent applications Over 25,000

Portfolio of pending and registered trademarks Over 7,000

R&D employees Roughly 2,700

R&D sites 35

More information on the specifics of today’s R&D press briefing can be found in the following publications:

• Biodegradable composites: a significant advance in medical implant technology

• Sustainability in aquaculture: Evonik turns salmon, shrimp, and other marine animals into vegetarians

• Evonik commercializes biosurfactants

More information on biosurfactants is available in the

current edition (No. 55) of “elements,” Evonik’s innovation

magazine.

The latest press releases published by Evonik Industries please also find in our press room on [www.evonik.com/press-releases](http://www.evonik.com/press-releases)

For more information you can visit our website :<http://corporate.evonik.de/en/media/publications/elements/Page> s/default.aspx

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders

in specialty chemicals. Profitable growth and a sustained increase in the value of

the company form the heart of Evonik’s corporate strategy. Its activities focus on

the key megatrends health, nutrition, resource efficiency and globalization. Evonik

benefits specifically from its innovative prowess and integrated technology

platforms.

Evonik is active in over 100 countries around the world. In fiscal 2015 more than

33,500 employees generated sales of around €13.5 billion and an operating profit

(adjusted EBITDA) of about €2.47 billion.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where

our statements concern the future, these forecasts, expectations or statements

may involve known or unknown risks and uncertainties. Actual results or

developments may vary, depending on changes in the operating environment.

Neither Evonik Industries AG nor its group companies assume an obligation to

update the forecasts, expectations or statements contained in this release.